7Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol, 1984, 15:291-298.
8Burnstein KL, Cidlowski JA. The down side of glucocorticoid receptor regulation. Mol Cell Endocrinol, 1992 ,83:C1-8.
9Crabtree GR, Smith KA, Munck A. Glucocorticoid receptors. In: Catovsky D, ed. Methods in Hematology. Vol.2. The leukemic cell. Edinburg, London, Melbourne and New York: Churchill Livingstone, 1981.252-269.
10Northrop JP, Crabtree GR, Mattila PS. Negative regulation of interleukin 2 transcription by the glucocorticoid receptor. J Exp Med, 1992, 175:1235-1245.
5Conti-Fine BM,Milani M,Kaminski HJ. Myasthenia gravis:past,present,and future[J].Journal of Clinical Investigation,2006.2843-2854.doi:10.1172/JCI29894.
6Benatar M. A systematic review of diagnostic studies in myasthenia gravis[J].Neuromuscular Disorders,2006,(7):459-467.doi:10.1016/j.nmd.2006.05.006.
7Luchanok U,Kaminski HJ. Ocular myasthenia:diagnostic and treatment recommendations and the evidence base[J].Current Opinion in Neurology,2008,(1):8-15.doi:10.1097/WCO.0b013e3282f4098e.
8Juel VC,Massey JM. Myasthenia gravis[J].ORPHANET JOURNAL OF RARE DISEASES,2007.44.doi:10.1186/1750-1172-2-44.
9Gajdos P,Chevret S,Toyka K. Intravenous immunoglobulin for myasthenia gravis[J].Cochrane Database of Systematic Reviews,2008,(01):CD002277.
10Skeie GO,Apostolski S,Evoli A. Guidelines for the treatment of autoimmune neuromuscular transmission disorders[J].European Journal of Neurology,2006.691-699.doi:10.1111/j.1468-1331.2006.01476.x.
